Anders Ullman
Director at Verona Pharma plc (VRNA)
Anders Ullman has filed 9 insider reports with the SEC since February 2021, as director at Verona Pharma plc (VRNA). Anders Ullman made no open-market purchases or sales in the last 12 months. The latest filing, on October 8, 2025, reports sale back to the company and exercise or conversion of a derivative at Verona Pharma plc (VRNA).
- Filings
- 9
- Companies
- 1
- Bought on market
- None
- Sold on market
- $20.9K
Companies where Anders Ullman is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 0 | $20.9K | Oct 8, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Oct 7, 2025VRNADirector Ullman Anders returned 430,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the companyForm 4Sale back to the companyExercise or conversion of a derivative
- Aug 1, 2025VRNADirector Ullman Anders converted options into 24,000 units of Ordinary Shares, increasing direct ownership by 7% to 358,856 unitsForm 4Exercise or conversion of a derivative
- Apr 25, 2025VRNASEC Form 4 filed by Director Ullman AndersForm 4Grant or award
- Apr 29, 2024VRNASEC Form 4 filed by Ullman AndersForm 4Grant or award
- Apr 28, 2023VRNASEC Form 4 filed by Ullman AndersForm 4Grant or award
- Apr 28, 2022VRNASEC Form 4 filed by Ullman AndersForm 4Grant or award
- Aug 9, 2021VRNASEC Form 4 filed by Ullman AndersForm 4Grant or award
- May 4, 2021-$10.1KVRNASEC Form 4: Ullman Anders sold $10,123 worth of Ordinary Shares (12,056 units at $0.84), decreasing direct ownership by 3% to 334,856 units (tax withholding)Form 4Open-market sale10b5-1 plan
Compare Anders Ullman with
- Anders Ullman vs Andrew Fisher1 shared
- Anders Ullman vs David Zaccardelli1 shared
- Anders Ullman vs Kathleen A. Rickard1 shared
- Anders Ullman vs Mark W Hahn1 shared
- Anders Ullman vs Michael Austwick1 shared
- Anders Ullman vs Mahendra Shah1 shared
Other insiders at the same companies
- Andrew FisherVRNA
- David ZaccardelliVRNA
- Kathleen A. RickardVRNA
- Mark W HahnVRNA
- Michael AustwickVRNA
- Mahendra ShahVRNA
- Vikas SinhaVRNA
- Lisa DeschampsVRNA
- David R EbsworthVRNA
- Martin EdwardsVRNA
- James Aloysius BradyVRNA
- Kenneth CunninghamVRNA
- Christina AckermannVRNA
Questions about Anders Ullman
- What is Anders Ullman's role at Verona Pharma plc?
- Anders Ullman reports to the SEC as director at Verona Pharma plc (VRNA), according to the latest filing on October 8, 2025.
- Has Anders Ullman bought or sold stock recently?
- The most recent open-market sale was on May 4, 2021: sold 12,056 shares of Verona Pharma plc (VRNA) for $10.1K at an average of $0.84.
- How do I get alerts when Anders Ullman files?
- Follow Anders Ullman on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Anders Ullman (SEC CIK 0001836816). Totals count each trade once, skipping amendments whose original is on file, from Feb 4, 2021 on. View on SEC EDGAR